Overview

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group, ambulatory safety and efficacy study of ARK-E021 topical foam of 5% and 10% in subjects with mild to moderate acne vulgaris.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M. Arkin 1999 Ltd.

Collaborators:

Foamix Ltd.
Vyne Therapeutics Inc.